Trial Profile

Phase Ib/II Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Relapsed/Refractory CD30+ Hodgkin's Lymphoma and CD30+ Non-Hodgkin's Lymphoma

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 31 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs TT 11 (Primary) ; Bendamustine; Fludarabine
Indications Hodgkin's disease; Non-Hodgkin's lymphoma
Focus Adverse reactions; Therapeutic Use
Acronyms ATLAS

Most Recent Events

29 Oct 2024 Planned End Date changed from 26 Aug 2040 to 26 Aug 2038.
29 Oct 2024 Planned primary completion date changed from 26 Aug 2025 to 10 Sep 2027.
07 Jul 2023 Planned End Date changed from 26 Aug 2038 to 26 Aug 2040.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com